移植物抗宿主疾病治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按疾病類型、產品、配銷通路、地區和競爭細分，2020-2030 年預測

2024 年全球移植物抗宿主疾病治療市場價值為 29.4 億美元，預計到 2030 年將達到 38 億美元，預測期內複合年成長率為 7.34%。移植物抗宿主疾病 (GVHD) 是在幹細胞或骨髓移植後可能發生的嚴重疾病。在 GVHD 中，捐贈者的免疫細胞會攻擊接受者的健康組織，導致各種併發症。醫療專業人員和患者對 GVHD 及其風險因素和症狀的認知越來越深刻。這種增強的認知可以促進早期診斷和干涉，這對於減輕 GVHD 的嚴重程度至關重要。白血病和淋巴瘤協會預計，2024 年將有 62,770 人被診斷出患有白血病。隨著早期診斷變得越來越普遍，對及時有效的 GVHD 治療的需求正在成長。 GVHD 治療市場專注於旨在控制或預防這種疾病的藥物和療法。移植中心的擴張不僅限於成熟的醫療保健市場，也延伸到新興地區。發展中國家正在增加對醫療保健基礎設施的投資，包括移植中心。此次全球擴張擴大了有資格接受移植的患者基礎，並隨後推動了本地和國際對 GVHD 治療的需求。幹細胞移植的日益普及刺激了 GVHD 治療領域的大量研究和開發工作。製藥公司和研究機構正在積極研究新型療法，包括單株抗體、免疫調節劑和細胞療法，專門用於針對和治療 GVHD。這些進步增強了醫療保健提供者的醫療設備，使他們能夠提供更量身定做、更有效的治療方案。監管機構認知到解決 GVHD 的重要性，並為 GVHD 治療的開發和批准提供支持。

主要市場促進因素

幹細胞移植越來越普遍

主要市場挑戰

治療費用高昂

主要市場趨勢

認知度和診斷水準不斷提高

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球移植物抗宿主疾病治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依疾病類型（急性移植物抗宿主疾病、慢性移植物抗宿主疾病）
  • 依產品（皮質類固醇、單株抗體、酪胺酸激酶抑制劑）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：北美移植物抗宿主疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲移植物抗宿主疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太地區移植物抗宿主疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲移植物抗宿主疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲移植物抗宿主疾病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如果有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Pfizer Inc
• Sanofi SA
• Astellas Pharma Inc
• Incyte Corporation
• Abbvie Inc
• Bristol-Myers Squibb Company
• F Hoffmann-La Roche Ltd

第 15 章：策略建議

第16章調查會社について,免責事項

Global Graft Versus Host Disease Treatment Market was valued at USD 2.94 Billion in 2024 and is expected to reach USD 3.80 Billion by 2030 with a CAGR of 7.34% during the forecast period. Graft Versus Host Disease (GVHD) is a severe medical condition that can occur after a stem cell or bone marrow transplant. In GVHD, the donor's immune cells attack the recipient's healthy tissues, leading to various complications. Medical professionals and patients are becoming more aware of GVHD, its risk factors, and its symptoms. This heightened awareness is leading to earlier diagnosis and intervention, which can be critical in mitigating the severity of GVHD. The Leukemia and Lymphoma Society projects that 62,770 individuals will be diagnosed with leukemia in 2024. As early diagnosis becomes more commonplace, the demand for prompt and effective GVHD treatments is growing. The GVHD Treatment Market focuses on pharmaceuticals and therapies aimed at managing or preventing this condition. The expansion of transplant centers is not limited to established healthcare markets but extends to emerging regions as well. Developing countries are increasingly investing in healthcare infrastructure, including transplant centers. This global expansion broadens the patient base eligible for transplantation and subsequently drives the demand for GVHD treatment, both locally and internationally. The increasing prevalence of stem cell transplants has spurred significant research and development efforts in the field of GVHD treatment. Pharmaceutical companies and research institutions are actively working on novel therapies, including monoclonal antibodies, immune modulators, and cellular therapies, specifically designed to target and treat GVHD. These advancements are enhancing the armamentarium of healthcare providers, enabling them to offer more tailored and effective treatment options. Regulatory agencies are recognizing the importance of addressing GVHD and are providing support for the development and approval of GVHD treatments.

Key Market Drivers

Increasing Prevalence of Stem Cell Transplants

The Global Graft Versus Host Disease (GVHD) Treatment Market is experiencing substantial growth, and one of the pivotal factors behind this expansion is the increasing prevalence of stem cell transplants. Stem cell transplantation has emerged as a powerful tool in the treatment of various hematological and immunological disorders. However, along with the rise in transplant procedures, the incidence of GVHD has also surged. Stem cell transplants, which include both autologous (using a patient's own stem cells) and allogeneic (using donor stem cells) procedures, have become a standard treatment option for a range of conditions. This increasing utilization is evident in the treatment of hematological malignancies like leukemia, lymphoma, and myeloma, as well as non-malignant disorders such as aplastic anemia and severe combined immunodeficiency (SCID). As the number of patients undergoing stem cell transplants rises, so does the potential for GVHD development.

Advancements in medical research and technology have expanded the indications for stem cell transplantation. Beyond traditional uses, researchers and clinicians are exploring transplantation for autoimmune diseases, solid organ transplant support, and regenerative medicine applications. This diversification in transplant indications is widening the patient pool at risk of developing GVHD, further driving the demand for effective GVHD treatments. GVHD is a common and potentially life-threatening complication following allogeneic stem cell transplantation. It occurs when the donor's immune cells recognize the recipient's tissues as foreign and launch an immune response, leading to inflammation and tissue damage. Given its prevalence, GVHD remains a significant concern in the transplantation community. Consequently, there is an ongoing need for innovative and effective treatments to manage this condition.

Key Market Challenges

High Treatment Costs

High treatment costs represent one of the most significant barriers in the GVHD treatment market, as patients face substantial financial challenges. The expenses associated with stem cell transplants, immunosuppressive therapies, and novel treatments such as CAR-T cell therapy often reach tens of thousands of dollars, making them unaffordable for many individuals. Stem cell transplants, for example, can cost upwards of $200,000, and even with insurance, out-of-pocket expenses may remain prohibitive. The high costs of these treatments can create disparities in patient access, particularly for those in low-income demographics or regions with limited healthcare coverage. patients who require long-term immunosuppressive therapy to manage GVHD may continue to incur substantial medical bills. These financial barriers can lead to delays or discontinuation of treatment, ultimately affecting patient outcomes. The rising costs of new, cutting-edge therapies may lead to increasing pressure on healthcare systems and insurance providers, forcing difficult decisions on the allocation of resources. As a result, addressing treatment costs through innovative pricing models, increased insurance coverage, or government funding initiatives is essential to ensure that all patients can access timely and effective care without facing financial hardship.

Key Market Trends

Growing Awareness and Diagnosis

The Global Graft Versus Host Disease (GVHD) Treatment Market is experiencing significant growth, and a pivotal driver behind this expansion is the increasing awareness of GVHD and the improved ability to diagnose the condition. GVHD is a complex and potentially life-threatening complication that can occur following stem cell or bone marrow transplantation. One of the key factors driving market growth is the increasing awareness of GVHD among healthcare professionals. For instance, The Leukemia and Lymphoma Society forecasts that new cases of leukemia, lymphoma, and myeloma will represent 9.4% of the estimated 2,001,140 new cancer cases to be diagnosed in the U.S. in 2024. Over the years, there has been a concerted effort to educate clinicians, transplant specialists, and nurses about the risk factors, signs, and symptoms of GVHD. This heightened awareness has led to more accurate and timely diagnosis, ensuring that GVHD patients receive appropriate care promptly.

In addition to healthcare professionals, GVHD awareness initiatives also target patients and their caregivers. Patients and their families are provided with information about the risks associated with transplantation and the potential development of GVHD. Armed with this knowledge, patients can recognize symptoms early, enabling them to seek medical attention quickly. As patient empowerment becomes more common, the demand for effective GVHD treatments rises. Early diagnosis of GVHD is paramount for successful treatment outcomes. With growing awareness, healthcare providers are more likely to suspect GVHD when patients present with specific symptoms, such as skin rashes, gastrointestinal issues, or liver abnormalities. Rapid diagnosis and intervention can prevent the progression of GVHD to severe and life-threatening stages, underscoring the importance of awareness campaigns. In May 2022, Novartis obtained approval from the European Commission (EC) for Jakavi (ruxolitinib) for the treatment of individuals aged 12 years and older who are experiencing acute or chronic GvHD and have not responded adequately to corticosteroids or other systemic treatments.

Key Market Players

• Pfizer Inc
• Sanofi SA
• Astellas Pharma Inc
• Incyte Corporation
• Abbvie Inc
• Bristol-Myers Squibb Company
• F Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Graft Versus Host Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Graft Versus Host Disease Treatment Market, By Disease Type:

• Acute Graft Versus Host Disease
• Chronic Graft Versus Host Disease

Graft Versus Host Disease Treatment Market, By Product:

• Corticosteroids
• Monoclonal Antibodies
• Tyrosine Kinase Inhibitors

Graft Versus Host Disease Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Graft Versus Host Disease Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Graft Versus Host Disease Treatment Market.

Available Customizations:

Global Graft Versus Host Disease Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Graft Versus Host Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease)
  • 5.2.2. By Product (Corticosteroids, Monoclonal Antibodies, Tyrosine Kinase Inhibitors)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Graft Versus Host Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Product
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Graft Versus Host Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Graft Versus Host Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Graft Versus Host Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Distribution Channel

7. Europe Graft Versus Host Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Product
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Graft Versus Host Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Graft Versus Host Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy Graft Versus Host Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France Graft Versus Host Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Graft Versus Host Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Graft Versus Host Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Product
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Graft Versus Host Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Graft Versus Host Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Graft Versus Host Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Graft Versus Host Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Graft Versus Host Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Distribution Channel

9. South America Graft Versus Host Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Product
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Graft Versus Host Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Graft Versus Host Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Graft Versus Host Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Graft Versus Host Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Product
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Graft Versus Host Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Graft Versus Host Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Graft Versus Host Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Pfizer Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Sanofi SA
• 14.3. Astellas Pharma Inc
• 14.4. Incyte Corporation
• 14.5. Abbvie Inc
• 14.6. Bristol-Myers Squibb Company
• 14.7. F Hoffmann-La Roche Ltd

15. Strategic Recommendations

16. About Us & Disclaimer